ROBERT F. APPLE - 16 Feb 2022 Form 4 Insider Report for ANTARES PHARMA, INC.

Role: President & CEO, Director
Signature: /s/ Lisa M. Kallebo as attorney-in-fact for Robert F. Apple
Issuer symbol: N/A
Transactions as of: 16 Feb 2022
Net transactions value: -$125,472
Form type: 4
Filing time: 18 Feb 2022, 18:13:18 UTC
Previous filing: 14 Jun 2021
Next filing: 04 Mar 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ATRS	Common Stock	Award	$0	+76,893	+3.2%	$0.000000	2,473,523	16 Feb 2022	Direct	F1
transaction	ATRS	Common Stock	Tax liability	$125,472	-34,282	-1.4%	$3.66	2,439,241	16 Feb 2022	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On June 13, 2019, Mr. Apple was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three-year performance period ended December 31, 2021. The number of shares acquired represent the total number of shares earned upon achievement of one of the performance goals, which was certified and vested on February 16, 2022. The shares of common stock disposed represents the number of shares withheld by the company to settle tax liabilities in connection with the vesting of the performance stock unit award and were not actually sold.

Content

On June 13, 2019, Mr. Apple was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three-year performance period ended December 31, 2021. The number of shares acquired represent the total number of shares earned upon achievement of one of the performance goals, which was certified and vested on February 16, 2022. The shares of common stock disposed represents the number of shares withheld by the company to settle tax liabilities in connection with the vesting of the performance stock unit award and were not actually sold.